20/20 BioLabs launches monthly investor webinar series starting July 1
20/20 BioLabs announced a monthly investor webinar series starting July 1, 2026, to improve transparency and shareholder communication. The webinars will provide direct access to management and updates on the company's progress. Attendees will receive a promotional discount code for OneTest, and replays will be available on the company's website.
*this image is generated using AI for illustrative purposes only.
20/20 BioLabs announced the launch of a recurring monthly investor webinar series designed to enhance transparency and strengthen shareholder communication. The inaugural webinar is scheduled for Wednesday, July 1, 2026, at 12:00 p.m. ET, with subsequent sessions planned for the first Wednesday of each month. The series aims to provide investors with direct access to management and a comprehensive view of the company's progress.
Webinar Details
The monthly webinars will run approximately 45 minutes, offering consistent updates on the company's developments. Below are the details for the inaugural session:
| Date | Wednesday, July 1, 2026 |
|---|---|
| Time | 12:00 p.m. Eastern time (9:00 a.m. Pacific time) |
| Webcast | Please click here to register |
Management Commentary
Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs, emphasized the importance of regular engagement with shareholders. "We believe our shareholders deserve regular access to management and a deeper understanding of our strategy, progress, and long-term vision," Cohen stated. "This webinar series is designed to provide investors with a direct line of communication to the company, increase transparency around our business, and create an ongoing forum to discuss the opportunities we see ahead."
Additional Offerings
Attendees of the webinar will receive a promotional discount code for a single OneTest, regardless of shareholder status. The company also noted that replays of the webinars will be available in the investor relations section of its website at https://2020biolabs.com .
About 20/20 BioLabs
20/20 BioLabs develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company offers two families of lab tests under the OneTest brand: OneTest for Cancer, a multi-cancer early detection (MCED) blood test, and OneTest for Longevity, which measures inflammatory biomarkers. Tests are conducted in the company's College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD.
What specific key performance indicators will management prioritize during these monthly updates?
How will the company measure the success of this webinar series in terms of shareholder engagement?
Could the increased transparency lead to more frequent updates on clinical trial timelines?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
